Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olpasiran - Amgen

Next Previous
Drug Profile

Olpasiran - Amgen

Alternative Names: AMG-890; ARC LPA; ARO LPA; RNAi ARC-LPA

Latest Information Update: 01 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arrowhead Pharmaceuticals
  • Developer Amgen
  • Class Cardiovascular therapies; Small interfering RNA
  • Mechanism of Action Lipoprotein A expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cardiovascular disorders

Most Recent Events

  • 22 Aug 2025 Amgen initiates the phase III OCEAN(a)-PreEvent trial for Cardiovascular disorders in USA, Australia, Canada (SC, Injection) (NCT07136012)
  • 23 Jul 2025 Amgen initiates an expanded-access programme for Cardiovascular disorders (NCT07079267)
  • 04 Feb 2025 Amgen plans a phase III (OCEAN(a)-CCTA trial for Cardiovascular disorders (In adults, In the elderly) in Denmark, France, Italy, Netherlands, Germany, Spain, Japan, China, Canada, Australia and the US (SC) in March 2026 (SC, Injection) (NCT07293260) (CTIS-2025-521117-88-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top